| Biomarker ID | 589 |
| PMID | 21305254 |
| Year | 2011 |
| Biomarker | Albumin (ALB); Rho GDP dissociation inhibitor (GDI) α (ARHGDIA); Keratin 18 (KRT18); Keratin 19 (KRT19); Keratin 8 (KRT8); |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Downregulated in Gleason Score 7(Fold Change) : Albumin (ALB) [2.155]; Rho GDP dissociation inhibitor (GDI) α (ARHGDIA) [2.571]; Keratin 18 (KRT18) [3.322]; Keratin 19 (KRT19) [4.950]; Keratin 8 (KRT8) [4.950]; |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(ALB):- HDL-mediated lipid transport,Transport of vitamins, nucleosides, and related molecules,Transport of organic anions,Folate metabolism,Vitamin B12 metabolism Pathways Include(GDI):-Membrane Trafficking,RAB GEFs exchange GTP for GDP on RABs,Rho GTPase cycle,Signal Transduction,Signaling by Rho GTPases,Vesicle-mediated transport |
| Experiment | Gleason Score 5 Vs Gleason Score 7 |
| Type of Biomarker | Prognostic |
| Cohort | Samples from 16 patients diagnosed with BPH along woth 8 patients with prostate cancer were chosen. 4 had Gleason Score 7 and 4 had Gleason Score 5. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | MALDI-TOF-MS |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | ALB, GDI, ARHGDIA, KRT18, KRT19, KRT8 |